BlackRock Group’s TherapeuticsMD TXMD Stock Holding History

BlackRock Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$706K	Buy	2,449 +404	+20%	+$125K	﹤0.01%	2255
2016 Q3	$695K	Buy	2,045 +57	+3%	+$20.8K	﹤0.01%	2189
2016 Q2	$845K	Buy	1,988 +1,060	+114%	+$437K	﹤0.01%	2043
2016 Q1	$297K	Buy	928 +418	+82%	+$143K	﹤0.01%	2438
2015 Q4	$264K	Sell	510 -363	-42%	-$134K	﹤0.01%	2439
2015 Q3	$256K	Buy	873 +466	+114%	+$166K	﹤0.01%	2450
2015 Q2	$160K	Buy	+407	New	+$144K	﹤0.01%	2633

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Group's TXMD Position: Q4 2016 in Review

BlackRock Group increased its TherapeuticsMD (TXMD) stake by 20% in Q4 2016, buying an estimated $125K and bringing the position to 2,449 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #2255.

BlackRock Group first reported a position in TXMD in Q2 2015 and has held it in 7 quarters since. The position peaked at $845K in Q2 2016. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

BlackRock Group held 2,449 shares of TherapeuticsMD worth $706K as of Q4 2016.
BlackRock Group bought 404 TherapeuticsMD shares in Q4 2016, an estimated $125K.
TherapeuticsMD made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2255 holding.
BlackRock Group first reported a position in TherapeuticsMD in Q2 2015 and has held it in 7 quarters since.
BlackRock Group's TherapeuticsMD position peaked at $845K in Q2 2016.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.